Objective
More than 60 million people are infected with HIV1, mostly in non-developed countries, and there is an urgent need for effective affordable treatment of HIV1 infections. The main objective of the project is to develop an efficient genetic vaccine candidate for therapeutic and preventive use against HIV/AIDS. This vaccine should be capable of inducing cell-mediated and humoral immunity against virus and virally infected cells in different phases of virus life-cycle. DNA vaccines could fulfil these requirements if rendered more efficient. To this aim, we will use the combination of complementary technologies brought in by four SMEs.
The novel DNA vaccination technology will combine:
(i) the restricted expression of the multi-epitope/multivalent HIV antigens in specific cells of the epidermis;
(ii) a micro-needle array based injection device for reproducible and efficient delivery into the epidermis;
(iii) the EPI-GTU® technology that allows strong and long term expression using segregation/partitioning function of the Bovine papillomavirus type 1;
(iv) the plasmo-VLP® technology that allow to express the immunogens within and onto virus-like-particles;
(v) the adjuvant effect of different cytokines.
The step-by-step combination of these technologies will be evaluated in the laboratories of the three academic partners by state of the art methods. The initial evaluation of vaccine efficacy will be performed in mice and pigs, and will be ultimately validated in cynomolgus monkeys. EPIVAC aims to conduct its pre-clinical development up to the GMP production and testing of vector batches that will be ready for evaluation in clinical trials.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- natural sciences biological sciences genetics DNA
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
TAMPERE
Finland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.